Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.
Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab (Darzalex) to the triplet regimen bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Dara-RVd) in patients with multiple myeloma.
In previous trials, RVd induction therapy performed well for both patients with transplant eligible disease as well as transplant ineligible, Voorhees says. In addition, the IFM 2009 trial showed that lenalidomide induction followed by transplant with lenalidomide consolidation and 1 year of lenalidomide maintenance demonstrated a complete response rate of 60% and median progression-free survival of 50 months.
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More